CAMBRIDGE, Mass., July 7 /PRNewswire-FirstCall/ -- Javelin Pharmaceuticals, Inc. (OTC Bulletin Board: JVPH - News), a specialty pharmaceutical company with three late-stage pain drug candidates, today announced it has been selected to receive a seven hundred and fifty thousand dollar grant to advance clinical development of PMI-150 (intranasal ketamine) for pain control. The grant, awarded through the Small Business Innovation Research (SBIR) program of the National Cancer Institute/National Institutes of Health (NCI/NIH), will support safety and efficacy studies of PMI-150 in a multi-center, randomized, double blind, placebo-controlled clinical trial in patients suffering from episodic acute moderate-to-severe pain.
